FTC’s Legal Intervention in Diovan Issue Possible, but Only with New Facts: Lawyer

Lawyer Noburo Gohara Novartis Pharma’s past promotions for its hypertension drug Diovan (valsartan) using manipulated clinical data could constitute a violation of the Antimonopoly Law, provoking Japan’s Fair Trade Commission (FTC) to take action, a lawyer says. In order for...read more